The introduction of policies for human papillomavirus vaccination in Europe

被引：4

作者：

Van Damme P. ^{[1
]}

Pecorelli S. ^{[2
]}

Joura E.A. ^{[3
]}

机构：

[1] Centre for the Evaluation of Vaccination, Vaccine and Infectious Diseases Institute, University of Antwerp, 2610 Antwerpen

[2] Department of Obstetrics and Gynaecology, Division of Gynaecologic Oncology, University of Brescia, Brescia

[3] Department of Obstetrics and Gynaecology, Medical University of Vienna, Vienna

来源：

Journal of Public Health | 2008年 / 16卷 / 4期

关键词：

HPV; Immunization policy; Vaccination;

D O I：

10.1007/s10389-008-0206-9

中图分类号：

学科分类号：

摘要：

Background: Human papillomavirus (HPV) vaccines represent a major advance in the prevention of cervical cancer and other HPV-related diseases. The availability of HPV vaccination and cervical cancer screening creates the unique opportunity to combine primary and secondary prevention of a cancer. HPV vaccination is currently being adopted in Europe at a faster rate than has been seen with most previous vaccines. Aims and methods: This article analyses the reasons for the rapid and broad access to this cancer prevention measure to illustrate the new sociopolitical environment that drives vaccination policies in the 21st century. Results: The promise of this intervention to prevent infection by the virus that can cause these diseases in young women created an environment receptive to vaccination. However, it was robust data generated by research specifically targeted to public health needs that have convinced various stakeholders to advocate, license, recommend, and fund vaccination. It was not just the usual host of actors who rallied to this process: early support for decision-making came from experts and scientific societies, patient and women's groups, and policy makers at the EU and national levels. Implementation now looms as the greatest challenge to vaccine uptake, in particular in the adolescent target group. Determinants of successful implementation include well-informed healthcare professionals who in turn can educate parents and adolescents on the infectious disease, its consequences, and the efficacy and safety of vaccination, and successful provision of equitable access to vaccination. The integration of vaccination and screening must also be carefully managed and adapted to the situation in each country. Conclusion: Inevitably, the impact of this promising public health intervention will depend upon the continuing engagement of all stakeholders to maintain interest and confidence in vaccination. © 2008 Springer-Verlag.

引用

页码：291 / 298

页数：7

共 69 条

[51] Paavonen J., Jenkins D., Bosch F.X., Naud P., Salmeron J., Wheeler C.M., Chow S.N., Apter D.L., Kitchener H.C., Castellsague X., De Carvalho N.S., Skinner S.R., Harper D.M., Hedrick J.A., Jaisamrarn U., Limson G.A., Dionne M., Quint W., Spiessens B., Peeters P., Struyf F., Wieting S.L., Lehtinen M.O., Dubin G., Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: An interim analysis of a phase I
[52] Declaration of the Prime-Minister before the Parliament, (2007)
[53] Postma M.J., Public Health Economics of Vaccines in the Netherlands methodological issues and applications, J Public Health, SUPPL., (2008)
[54] Raffle A.E., Challenges of implementing human papillomavirus (HPV) vaccination policy, BMJ, 335, pp. 375-377, (2007)
[55] Siegrist C.A., Balinska M.A., The public perception of the value of vaccines, J Public Health, SUPPL., (2008)
[56] Skinner S.R., Kang M., Rosenthal S.L., Vaccinating young adults against human papillomavirus: The importance of understanding health decision-making and behaviour, Sexual Health, 4, pp. 129-132, (2007)
[57] Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ:a combined analysis of four randomised clinical trials, Lancet, 369, pp. 1861-1868, (2007)
[58] Van Ballegooijen M., Van Den Akker-Van M., Patnick J., Lynge E., Arbyn M., Anttila A., Ronco G., Dik J., Habbema F., Overview of important cervical cancer screening process values in European Union (EU) countries, and tentative predictions of the corresponding effectiveness and cost-effectiveness, Eur J Cancer, 36, pp. 2177-2188, (2000)
[59] Van Der Zeijst B.A., Dijkman M.I., Luytjes W., Van Alphen A.J., Van Den Dobbelsteen G.P., On the design of national vaccination programmes, Vaccine, 25, pp. 3143-3145, (2007)
[60] Villa L.L., Perez G., Kjaer S.K., Paavonen J., Lehtinen M., Munoz N., Sigurdsson K., Hernandez-Avila M., Skjeldestad F.E., Thoresen S., Garcia P., Majewski S., Dillner J., Olsson S.E., Tay E.H., Bosch F.X., Ault K.A., Brown D.R., Ferris D.G., Koutsky L.A., Kurman R.J., Myers E.R., Barr E., Boslego J., Bryan J., Esser M.T., Gause C.K., Hesley T.M., Lupinacci L.C., Sings H.L., Taddeo F.J., Thornton A.R., Boulos M., Cox J.T., Langmark F., Modlin J., Munoz A., Odlind V., Wilkinson E., Ferenczy A.,

← 1 2 3 4 5 6 7 →